tiprankstipranks
Theravance Biopharma (TBPH)
NASDAQ:TBPH
US Market
TBPH
Theravance Biopharma
RESEARCH TOOLSreports
Want to see TBPH full AI Analyst Report?

Theravance Biopharma (TBPH) Income Statement

353 Followers

Theravance Biopharma Income Statement

Last quarter (Q4 2025), Theravance Biopharma's total revenue was $45.89M, an increase of 144.70% from the same quarter last year. In Q4, Theravance Biopharma's net income was $61.02M. See Theravance Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 107.46M$ 64.38M$ 57.42M$ 51.35M$ 55.31M
Gross Profit
$ 101.95M$ 64.38M$ 16.80M$ -12.05M$ -138.35M
Operating Expenses
$ 115.19M$ 111.33M$ 72.84M$ 79.91M$ 119.44M
Depreciation and Amortization
$ 5.51M$ 3.62M$ 2.00M$ 3.04M$ 4.81M
EBITDA
$ -7.73M$ -38.45M$ -51.65M$ -76.08M$ -232.83M
Operating Income
$ -13.25M$ -46.95M$ -56.03M$ -91.96M$ -257.78M
Other Income/Expenses
$ 142.49M$ 2.33M$ 6.77M$ -858.00K$ -7.44M
Pretax Income
$ 129.25M$ -44.61M$ -49.27M$ -92.81M$ -265.22M
Net Income
$ 105.89M$ -56.42M$ -55.19M$ 872.13M$ -199.43M
Per Share Metrics
Basic EPS
$ 2.10$ -1.15$ -1.00$ -1.26$ -2.87
Diluted EPS
$ 2.06$ -1.15$ -1.00$ -1.26$ -2.87
Weighted Average Shares Outstanding
 50.32M 48.85M 55.30M 73.59M 69.46M
Weighted Average Shares Outstanding (Diluted)
 51.51M 48.85M 55.30M 73.59M 69.46M
Currency in USD

Theravance Biopharma Earnings and Revenue History